Neurocrine Biosciences
NBIX
#1397
Rank
S$19.51 B
Marketcap
S$195.70
Share price
-1.34%
Change (1 day)
9.10%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2025 (TTM): S$5.61

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$5.55. In 2024 the company made an earnings per share (EPS) of S$4.35 an increase over its 2023 EPS that were of S$3.27.

EPS history for Neurocrine Biosciences from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)S$5.6129.02%
2024S$4.3533.07%
2023S$3.2757.76%
2022S$2.0769.47%
2021S$1.22-78.21%
2020S$5.61990%
2019S$0.5281.82%
2018S$0.28-113.5%
2017S-$2.100.62%
2016S-$2.0957.28%
2015S-$1.3325.61%
2014S-$1.0618.84%
2013S-$0.89-1085.71%
2012S$0.09013

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Repligen
RGEN
S$0.03863-99.30%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.27-59.02%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
S-$38.50-793.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$26.42 376.06%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$1.74-68.63%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
S$2.21-60.09%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$2.20-60.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.61-147.10%๐Ÿ‡บ๐Ÿ‡ธ USA